Table 3.
Associations between cit-Fib reactivity and serological (anti CCP2 and anti-cit-Fib) and genetic risk markers (HLA-DR SE and PTPN22 risk allele)
| All patients (n = 347) | Anti CCP2 (n = 347) | Anti-cit-Fib (n = 346) | |||||
|---|---|---|---|---|---|---|---|
| No | Yes | P value | No | Yes | P value | ||
| Cit-Fib α 35 | 70 (20.2) | 0 (0) | 70 (28.0) | <0.0001 | 3 (1.9) | 66 (34.74) | <0.0001 |
| Cit-Fib α 216,218 | 44 (12.7) | 2 (2.1) | 42 (16.8) | 0.0001 | 13 (8.3) | 31 (16.32) | 0.03 |
| Cit-Fib α 263,271 | 73 (21.0) | 1 (1.0) | 72 (28.8) | <0.0001 | 8 (5.1) | 64 (33.68) | <0.0001 |
| Cit-Fib α 425,426 | 59 (17.0) | 2 (2.1) | 57 (22.8) | <0.0001 | 14 (9) | 45 (23.68) | 0.0003 |
| Reactivity to at least one cit-Fib peptide | 168 (48.4) | 3 (3.1) | 165 (66.0) | <0.0001 | 29 (18.6) | 138 (72.63) | <0.0001 |
| HLA-DR SE (n = 326) | PTPN22 C1858T (n = 322) | ||||||
| Cit-Fib α 35 | 70 (20.2) | 11 (15.1) | 55 (21.74) | 0.21 | 38 (17.4) | 28 (27.18) | 0.04 |
| Cit-Fib α 216,218 | 44 (12.7) | 12 (16.4) | 30 (11.86) | 0.30 | 32 (14.8) | 9 (8.74) | 0.14 |
| Cit-Fib α 263,271 | 73 (21.0) | 13 (17.8) | 57 (22.53) | 0.39 | 39 (17.8) | 30 (29.13) | 0.02 |
| Cit-Fib α 425,426 | 59 (17.0) | 10 (13.7) | 46 (18.18) | 0.37 | 34 (15.5) | 23 (22.33) | 0.14 |
| Reactivity to at least one cit-Fib peptide | 168 (48.4) | 34 (46.6) | 124 (49.01) | 0.71 | 99 (45.2) | 58 (56.31) | 0.06 |
| Anti-cit Fib protein | 190 (54.9) | 29 (40.3) | 147 (58.1) | 0.01 | 106 (48.6) | 69 (67.0) | 0.003 |
Data represent the numbers (percentage) and p values (uncorrected for multiple comparisons). Cit-Fib citrullinated fibrinogen, CCP cyclic citrullinated peptides, SE shared epitope